-
公开(公告)号:US10434139B2
公开(公告)日:2019-10-08
申请号:US15410448
申请日:2017-01-19
发明人: Ivan Coulter
IPC分类号: A61K9/00 , A61K9/50 , A61K38/13 , A61K38/28 , A61K39/00 , A61K45/06 , A61K31/436 , A61K31/439 , A61K31/635 , A61K35/741
摘要: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximize absorption and/or therapeutic efficiency.
-
公开(公告)号:US09980902B2
公开(公告)日:2018-05-29
申请号:US15090377
申请日:2016-04-04
发明人: Ivan Coulter , Vincenzo Aversa
IPC分类号: A61K31/58 , A61K9/16 , A61K9/00 , A61K31/502 , A61K38/13 , A61K31/223 , A61K31/56 , A61K9/50 , A61K9/48
CPC分类号: A61K9/0053 , A61K9/16 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/1658 , A61K9/1694 , A61K9/4808 , A61K9/4891 , A61K9/50 , A61K9/5036 , A61K9/5042 , A61K31/223 , A61K31/502 , A61K31/56 , A61K31/58 , A61K38/13 , A61K2300/00
摘要: A method for treating intestinal fibrosis in a subject, comprising enterally administering a steroid to the subject. The steroid may be in a multiple minibead formulation.
-
公开(公告)号:US20160213611A1
公开(公告)日:2016-07-28
申请号:US15090377
申请日:2016-04-04
发明人: Ivan Coulter , Vincenzo Aversa
CPC分类号: A61K9/0053 , A61K9/16 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/1658 , A61K9/1694 , A61K9/4808 , A61K9/4891 , A61K9/50 , A61K9/5036 , A61K9/5042 , A61K31/223 , A61K31/502 , A61K31/56 , A61K31/58 , A61K38/13 , A61K2300/00
摘要: A method for treating intestinal fibrosis in a subject, comprising enterally administering a steroid to the subject. The steroid may be in a multiple minibead formulation.
摘要翻译: 一种用于治疗受试者的肠纤维化的方法,包括向所述受试者肠内施用类固醇。 类固醇可以是多重微型制剂。
-
公开(公告)号:US20160045585A1
公开(公告)日:2016-02-18
申请号:US14924641
申请日:2015-10-27
IPC分类号: A61K39/108 , A61K39/02 , A61K39/08 , A61K9/50 , A61K39/12 , A61K39/00 , A61K39/39 , A61K9/06 , A61K39/112
CPC分类号: A61K39/0258 , A61K9/06 , A61K9/146 , A61K9/50 , A61K9/5042 , A61K9/5073 , A61K9/5161 , A61K39/0002 , A61K39/0208 , A61K39/0283 , A61K39/08 , A61K39/107 , A61K39/12 , A61K39/39 , A61K47/36 , A61K2039/52 , A61K2039/521 , A61K2039/522 , A61K2039/525 , A61K2039/5252 , A61K2039/5254 , A61K2039/54 , A61K2039/542 , A61K2039/55511 , Y02A50/474
摘要: This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material comprises a microorganism. In particular, the invention relates to compositions comprising a microorganism selected from live, killed, attenuated and inactivated microorganisms. The matrix material may also comprise a surfactant and may further comprise an adjuvant. The invention further relates to the manufacture and use of such compositions, and to other subject matter.
摘要翻译: 本发明涉及用于递送一种或多种活性成分的组合物,更具体地涉及组合物,例如, 珠粒,其包含基质材料,该基质材料包含微生物。 特别地,本发明涉及包含选自活的,灭活的,减毒的和灭活的微生物的微生物的组合物。 基质材料还可以包含表面活性剂,并且还可以包含佐剂。 本发明还涉及这种组合物的制造和使用以及其它主题。
-
公开(公告)号:US20130330411A1
公开(公告)日:2013-12-12
申请号:US13942492
申请日:2013-07-15
发明人: Ivan Coulter
CPC分类号: A61K38/13 , A61K9/0053 , A61K9/50 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5057 , A61K9/5073 , A61K9/5089 , A61K31/436 , A61K31/439 , A61K31/635 , A61K35/741 , A61K38/28 , A61K39/0005 , A61K45/06 , A61K2039/55583
摘要: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].
摘要翻译: 口服环孢菌素组合物包含具有包含环孢菌素的核心的微囊,特别是溶解液体形式的环孢菌素A. 小分子具有至少在结肠中释放预增溶的环孢菌素的释放曲线。 该组合物可用于治疗一系列肠道疾病。 10]。
-
公开(公告)号:US20170196934A1
公开(公告)日:2017-07-13
申请号:US15410448
申请日:2017-01-19
发明人: Ivan Coulter
IPC分类号: A61K38/13 , A61K9/50 , A61K9/00 , A61K31/436
CPC分类号: A61K38/13 , A61K9/0053 , A61K9/50 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5057 , A61K9/5073 , A61K9/5089 , A61K31/436 , A61K31/439 , A61K31/635 , A61K35/741 , A61K38/28 , A61K39/0005 , A61K45/06 , A61K2039/55583
摘要: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximise absorption and/or therapeutic efficiency.
-
公开(公告)号:US09675558B2
公开(公告)日:2017-06-13
申请号:US15051356
申请日:2016-02-23
发明人: Ivan Coulter
IPC分类号: A61K38/13 , A61K9/50 , A61K31/436 , A61K9/00 , A61K45/06 , A61K31/439 , A61K31/635 , A61K38/28 , A61K39/00
CPC分类号: A61K38/13 , A61K9/0053 , A61K9/50 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5057 , A61K9/5073 , A61K9/5089 , A61K31/436 , A61K31/439 , A61K31/635 , A61K35/741 , A61K38/28 , A61K39/0005 , A61K45/06 , A61K2039/55583
摘要: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.
-
公开(公告)号:US20160317609A1
公开(公告)日:2016-11-03
申请号:US15034844
申请日:2014-11-07
发明人: Ivan Coulter , Vincenzo Aversa , Monica Rosa
CPC分类号: A61K38/13 , A61K9/0053 , A61K9/4808 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K9/5036 , A61K9/5047 , A61K9/5073
摘要: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.
摘要翻译: 一种包含口服给药的环孢菌素A的改良组合物。 组合物可以包含芯和改性释放包衣,其中芯包含形成水凝胶的聚合物基质和环孢菌素A.组合物可以是微型载体的形式。 组合物提供药代动力学特征和溶出曲线,其提供在下GI胃中释放环孢菌素A,同时使全身暴露最小化。 还公开了该组合物在治疗影响下胃肠道,特别是结肠的病症中的用途。
-
公开(公告)号:US20160143989A1
公开(公告)日:2016-05-26
申请号:US15011372
申请日:2016-01-29
CPC分类号: A61K38/13 , A61K9/107 , A61K9/1075 , A61K9/1617 , A61K9/1635 , A61K9/1652 , A61K9/1658 , A61K9/1694 , A61K9/5026 , A61K9/5036 , A61K9/5047 , A61K9/5073 , A61K31/436 , A61K38/00 , A61K47/10 , A61K47/14 , A61K47/44 , Y02A50/465 , Y02A50/471 , Y02A50/473
摘要: A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are free of active principle. The oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant.
摘要翻译: 组合物包含其中分散有油滴的水溶性聚合物基质,该组合物包含活性成分。 本发明包括其中有效原理包括在至少一些油滴中的实施方案以及其中油滴没有主动原理的实施方案。 当含有它们的基质溶解在水性介质中时,油滴被释放。 在一个实施方案中,油滴基本上固定在基质中或由基质固定,并且当基质溶解在水性介质中时,固定化特征丧失。 在某些实施方案中,油滴可统称为本发明组合物的油相。 该产品可以是迷你珠的形式。 油相和/或聚合物基质可各自包括表面活性剂。
-
公开(公告)号:US20180360909A1
公开(公告)日:2018-12-20
申请号:US16110795
申请日:2018-08-23
发明人: Ivan Coulter , Vincenzo Aversa , Monica Rosa
摘要: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.
-
-
-
-
-
-
-
-
-